DelveInsight’s, “Post-Traumatic Stress Disorder Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Post-Traumatic Stress Disorder pipeline landscape. It covers the pipeline drug profiles, including Post-Traumatic Stress Disorder clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Post-Traumatic Stress Disorder pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-traumatic stress disorders collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Post-Traumatic Stress Disorder Pipeline Report
- DelveInsight’s post-traumatic stress disorder pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for post-traumatic stress disorder treatment.
- The leading post-traumatic stress disorder companies such as Aptinyx, Nobilis Therapeutics Inc., Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., Halucenex Life Sciences, Bionorica SE, MAPS Europe B.V., Hoffmann-La Roche, Praxis Precision Medicines, Alto Neuroscience, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Psy Therapeutics Inc, Chronos Therapeutics, Mydecine Innovations Group, ATAI LIFE SCIENCES N.V., Acer Therapeutics, Alzamend Neuro, Inc., Innovation1 Biotech Inc., Lophora, Virpax Pharmaceuticals, Alto Neuroscience, VistaGen, ANANDA Scientific, Bright Minds Biosciences, and others
- Promising post-traumatic stress disorder pipeline therapies in various stages of development include NYX-783, NBTX-001, JZP150, Psilocybin, BNC210, BI 1358894, Brexpiprazole, BX-1, MDMA, Balovaptan, PRAX-114, ALTO-100, Lu AG06466, TNX-102, PSY-05, TrkB Modulator, MYCO-001, EMP-01 / MDMA derivative, ACER-801, AL001, Psilocin Prodrug, PES200, ALTO-100, ALTO-202, Liquid Structure™ Cannabidiol (CBD), and others.
- Post-Traumatic Stress Disorder Companies and academics are working to assess challenges and seek opportunities that could influence Post-traumatic stress disorders R&D. The Post-Traumatic Stress Disorder pipeline therapies under development are focused on novel approaches to treat/improve Post-traumatic stress disorders.
To explore more information on the latest breakthroughs in the Post-Traumatic Stress Disorder pipeline treatment landscape of the report, click here @ Post-Traumatic Stress Disorder Pipeline Outlook
Post-Traumatic Stress Disorder Overview
Post-traumatic stress disorder (PTSD) is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape or who have been threatened with death, sexual violence or serious injury Some experiences, like the sudden, unexpected death of a loved one, can cause PTSD.
Recent Developments Activities in the Post-Traumatic Stress Disorder Treatment Landscape
- In October 2022, Acer Therapeutics Inc. announced the expansion of ACER-801 (osanetant) into a new indication for the reduction of the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD).
- In September 2022, atai Life Sciences N.V., which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced it’s Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.
- In May 2022, data from preclinical studies of Aptinyx’s NYX-783 in models of post-traumatic stress disorder (PTSD) were presented in a poster at the American Psychiatric Association Annual Meeting which was held from May 21 – 25, 2022, in New Orleans, LA.
- In May 2022, Beckley Psytech Limited and Lophora ApS announced the companies had entered into a research and development collaboration. Under the terms of the agreement, Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D.
- In May 2022, The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announced a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD). The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA).
- In February 2022, Novamind Inc. announced that it is enrolling participants in phase II clinical trial sponsored by Alto Neuroscience. The eight-week clinical trial currently underway at Novamind’s Draper, Utah research site is investigating an antidepressant medication for adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (the “Alto Clinical Trial”).
- In December 2021, Jazz Pharmaceuticals plc announced that the first patient had been enrolled in Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). JZP150 is a highly selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), designed to address the underlying cause of PTSD (impairment of fear extinction and its consolidation), as well as patients’ associated symptoms (anxiety, insomnia, and nightmares).
Request a sample and discover the recent advances in Post-Traumatic Stress Disorder Ongoing Clinical Trial Analysis and Medications, click here @ Post-Traumatic Stress Disorder Treatment Landscape
Post-traumatic stress disorders Emerging Drugs Profile
- Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization
Brexpiprazole is a Dopamine D2 receptor partial agonists being developed by Otsuka Pharmaceutical Development and Commercialization in a Phase III clinical trial for Post-Traumatic stress disorder. Brexpiprazole as Combination Therapy with Sertraline is tested in the Adults with Post-traumatic Stress Disorder. This trail is expected to get completed in June 2022.
- NBTX-001 Xenon Inhaler: Nobilis Therapeutics
NBTX-001 is a uniquely engineered drug-device combination specifically designed to provide a differentiated pharmaceutical therapy for the treatment of PTSD. Its proprietary portable inhalation device delivers a xenon gas mixture that has an exceptional safety profile proven by decades of clinical use in general anesthesia. Xenon is a competitive NMDA receptor antagonist devoid of dissociative and habit-forming properties. XBTX-001 is under phase II/III for PTSD.
- BNC 210: Bionomics
BNC210 is Bionomics’ proprietary molecule in development for the treatment of Social Anxiety Disorder (SAD), Post-Traumatic Stress Disorder (PTSD) and anxiety disorders. Bionomics is conducting a phase II trial to assess the effects of BNC210 compared to placebo on PTSD symptom severity. BNC 210 blocks the alpha7 nicotinic acetylcholine receptor. BNC210 has also demonstrated a well-tolerated safety profile which indicates a potential advantage over currently available medications for the treatment of SAD, PTSD and anxiety disorders (e.g. antidepressants, benzodiazepines).
- Lu AG06466: H. Lundbeck A/S
Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). H.Lundbeck A/S is conducting Phase I trial for Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.
Post-traumatic Stress Disorder Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Post-traumatic stress disorders. The companies which have their Post-traumatic stress disorders drug candidates in the most advanced stage, i.e. phase III include, Otsuka Pharmaceutical Development & Commercialization.
For further information, refer to the detailed Post-traumatic Stress Disorder Unmet Needs, Post-traumatic Stress Disorder Market Drivers, and Market Barriers, click here for Post-traumatic Stress Disorder Ongoing Clinical Trial Analysis
Scope of the Post-traumatic Stress Disorder Pipeline Report
- Coverage- Global
- Post-Traumatic Stress Disorders Companies- Aptinyx, Nobilis Therapeutics Inc., Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., Halucenex Life Sciences, Bionorica SE, MAPS Europe B.V., Hoffmann-La Roche, Praxis Precision Medicines, Alto Neuroscience, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Psy Therapeutics Inc, Chronos Therapeutics, Mydecine Innovations Group, ATAI LIFE SCIENCES N.V., Acer Therapeutics, Alzamend Neuro, Inc., Innovation1 Biotech Inc., Lophora, Virpax Pharmaceuticals, Alto Neuroscience, VistaGen, ANANDA Scientific, Bright Minds Biosciences, and others
- Post-Traumatic Stress Disorders Pipeline Therapies- NYX-783, NBTX-001, JZP150, Psilocybin, BNC210, BI 1358894, Brexpiprazole, BX-1, MDMA, Balovaptan, PRAX-114, ALTO-100, Lu AG06466, TNX-102, PSY-05, TrkB Modulator, MYCO-001, EMP-01 / MDMA derivative, ACER-801, AL001, Psilocin Prodrug, PES200, ALTO-100, ALTO-202, Liquid Structure™ Cannabidiol (CBD), and others.
- Post-Traumatic Stress Disorders Pipeline Segmentation: Product Type, Molecule Type, Route of administration, Mechanism of action
Dive deep into rich insights for drugs for Post-traumatic stress disorders Market Drivers and Post-traumatic stress disorders Market Barriers, click here @ Post-traumatic stress disorders Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Post-traumatic stress disorders: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Post-traumatic stress disorders – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- NBTX-00: Nobilis Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BNC 210: Bionomics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Lu AG06466: H. Lundbeck A/S
- Drug profiles in the detailed report…..
- Inactive Products
- Post-traumatic stress disorders Key Companies
- Post-traumatic stress disorders Key Products
- Post-traumatic stress disorders- Unmet Needs
- Post-traumatic stress disorders- Market Drivers and Barriers
- Post-traumatic stress disorders- Future Perspectives and Conclusion
- Post-traumatic stress disorders Analyst Views
- Post-traumatic stress disorders Key Companies
- Appendix
Got Queries? Find out the related information on Post-traumatic Stress Disorder Mergers and acquisitions, Post-traumatic Stress Disorder Licensing activities @ Post-traumatic Stress Disorder Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/